Clinical trials: Checkpoint Inhibitor
Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor
Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed promising results, but all data…
- Conditions
- Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation
- Trial name
- NCT04867330
- Testing
- Toxicities reduced treatment arm
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed…
- Trial name
- NCT04826406
- Testing
- Camrelizumab combined Apatinib regimen
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hunan Cancer Hospital
Autoimmune Diseases, Checkpoint Inhibitor
Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease
Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy.
- Conditions
- Autoimmune Diseases, Checkpoint Inhibitor, Immunotherapy
- Trial name
- CIAD (NCT04805099)
- Testing
- Checkpoint inhibitor
- Where
- Greece
- Volunteers
- 126 people
- Sponsor
- Hellenic Cooperative Oncology Group
Hodgkin Lymphoma, Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
This is an observational retrospective study to investigate the efficacy and safety of the treatment with an immune checkpoint inhibitor (nivolumab or pembrolizumab) in combination with radiotherapy in patients with…
- Conditions
- Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
- Trial name
- ICI-RT-1 (NCT04419441)
- Testing
- Immune checkpoint inhibitor
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Ospedale Maggiore Di Trieste
Adverse Reactions, Immune Checkpoint Inhibitor
Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients
This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included .
- Conditions
- Adverse Reactions, Immune Checkpoint Inhibitor, Non-Small Cell Lung Cancer Patients, Cardiac Event
- Trial name
- NCT04473703
- Testing
- renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer Metastatic, Treatment Adverse Effect
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
This is an observational, retrospective and monocentric study, conducted at the university Hospital of Brest The primary objective is to assess the association between the occurrence of thyroid dysfunction in patients treated…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Treatment Adverse Effect, Thyroid Dysfunction, Immune Checkpoint Inhibitor
- Trial name
- THYRONIVO (NCT04470440)
- Where
- France
- Volunteers
- 134 people
- Sponsor
- University Hospital, Brest
Immune Checkpoint Inhibitor, Chemotherapy Effect
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
- Conditions
- Immune Checkpoint Inhibitor, Chemotherapy Effect, Epigenetic Disorder, NK/T-cell Lymphoma of Nasal Cavity
- Trial name
- NCT04414969
- Testing
- Anti-PD-1 antibody+Peg-Asparaginase+Chidamide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Hunan Cancer Hospital